Hoth Therapeutics, Inc. (HOTH) said that it has signed an agreement with LTS Therapy Systems LLC, to develop and manufacture the HT-ALZ oral film prototype. HT-ALZ is being developed as a novel therapeutic solution for Alzheimer's Disease based on its exciting preclinical results released earlier this year.
HT-ALZ's pre-clinical significance lies in its ability to restore cognitive functions and improve quality of life for subjects suffering from Alzheimer's disease.
The HT-ALZ prototype development and manufacturing work by LTS will be used to support a future Investigational New Drug Application to initiate clinical trials.
In pre-market, the shares were gaining 45.82 percent to trade at $1.40.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.